• Molecular NameAuranofin
  • SynonymAuroafen
  • Weight364.371
  • Drugbank_IDDB00995
  • ACS_NO34031-32-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.3
  • pkaN/A
  • LogD (pH=7, predicted)-0.76
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.26
  • LogSw (predicted, AB/LogsW2.0)1.15
  • Sw (mg/ml) (predicted, ACD/Labs)1.94
  • No.of HBond Donors0
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds9
  • TPSA153.23
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA organogold compound classified by the World Health Organization as an antirheumatic agent.
  • Absorption_valueN/A
  • Absorption (description)Because of rapid metabolism, intact auranofin has never been detected in the blood. Approximately 25% of the gold in auranofin is absorbed. Steady-state gold concentrations of approximately 0.68 mcg/mL are achieved in approximately 3 months.
  • Caco_2N/A
  • Bioavailability20.0
  • Protein binding60.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmRapidly metabolized.
  • Half lifeMean terminal plasma t ? of auranofin gold at steady-state is 26 days.
  • ExcretionApproximately 60% of absorbed gold of single auranofin dose is excreted in urine; remainder is excreted in the feces.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOral, rat: LD50 = > 2000 mg/kg. Symptoms of overdose may include diarrhoea, vomiting, abdominal cramps, and symptoms of hypersensitivity (such as skin rash, hives, itching, and difficulty breathing).
  • LD50 (rat)N/A
  • LD50 (mouse)N/A